Financial statements Amorphis Pharma Development
Balance sheet of Amorphis Pharma Development
Company age:
Age:
6 y. 11 m. 28 d.
Share capital:
Share capital:
5 000 PLN
Company suspended its operations from 2024-01-01
Balance sheet data of AMORPHIS PHARMA DEVELOPMENT
|
Year
|
2018
|
2020
|
2021
|
2022
|
2023
|
|---|---|---|---|---|---|
| Total assets | 1 370 069,54 | 1 200 728,90 | 1 164 631,51 | 1 047 158,64 | 1 032 357,30 |
| A. Fixed assets | 300 000,00 | 626 658,90 | 847 586,78 | 881 698,55 | 998 398,91 |
| B. Current assets | 1 070 069,54 | 574 070,00 | 317 044,73 | 165 460,09 | 33 958,39 |
| C. Share capital contributions (basic funds) | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| D. Own shares (stocks) | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| Total liabilities | 1 370 069,54 | 1 200 728,90 | 1 164 631,51 | 1 047 158,64 | 1 032 357,30 |
| A. Equity | 511 737,18 | 520 327,12 | 520 479,72 | 456 147,61 | 457 863,58 |
| B. Liabilities and provisions for liabilities | 858 332,36 | 680 401,78 | 644 151,79 | 591 011,03 | 574 493,72 |
| I. Long-term liabilities | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| II. Short-term liabilities | 1 412,41 | 29 540,51 | 21 978,53 | 3 289,11 | 42,90 |
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.
- Fixed Assets - Assets held for a longer period, typically longer than a year, such as real estate or machinery.
- Current Assets - Assets intended to be used or sold within a year, such as inventory, receivables, and cash.
- Equity - The net value of a company's assets, representing the difference between its assets and liabilities.
- Long-Term Liabilities - Financial obligations to be repaid over a period longer than a year, such as loans or bonds.
- Short-Term Liabilities - Financial obligations to be repaid within a year, such as payables to suppliers or short-term loans.
- Reserve Capital - A portion of equity set aside for specific purposes, such as covering losses or business development.